Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing disease-modifying therapies for Alzheimer's disease by targeting soluble amyloid-beta oligomers, which are believed to be primary toxins in disease progression. The company's lead candidate, sabirnetug, is a monoclonal antibody designed to selectively neutralize these toxic oligomers with significantly higher specificity than existing therapies, administered intravenously with a subcutaneous formulation in development. The company generates revenue through milestone payments and royalty arrangements from partnerships with major pharmaceutical and biotechnology firms, contingent on successful clinical trial results and regulatory approval, while the addressable market encompasses millions of patients globally with mild cognitive impairment or mild dementia due to Alzheimer's disease.